Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?

BMC Pulmonary Medicine

Volumn 11, Issue , 2011, Pages

  Hennigs, Jan K ^a   Keller, Gunhild ^a   Baumann, Hans J ^a   Honecker, Friedemann ^a   Kluge, Stefan ^a   Bokemeyer, Carsten ^a   Brümmendorf, Tim H ^a   Klose, Hans ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Pulmonary hypertensiondrug inducedantiproliferative therapyleukaemia; side effects

Indexed keywords

ALPHA INTERFERON; DASATINIB; HYDROXYUREA; IMATINIB; SILDENAFIL; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; HUMAN; LABORATORY TEST; LONG TERM CARE; LOW DRUG DOSE; MALE; PROGNOSIS; PULMONARY HYPERTENSION; CHEMICALLY INDUCED DISORDER; CHRONIC MYELOID LEUKEMIA; DRUG ANTAGONISM; TREATMENT OUTCOME;

AGED; HUMANS; HYPERTENSION, PULMONARY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; THIAZOLES; TREATMENT OUTCOME;

EID: 79956196545     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-11-30     Document Type: Article

References (19)

1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004, 351(14):1425-1436. 10.1056/NEJMra040291, 15459304.
2. Michelakis ED, Weir EK. Anorectic drugs and pulmonary hypertension from the bedside to the bench. Am J Med Sci 2001, 321(4):292-299. 10.1097/00000441-200104000-00009, 11307870.
3. EMEA Sprycel - Scientific Discussion. European Public Assessment Report (EPAR) 2008, (EMEA/H/C/709), EMEA.
4. FDA Dasatinib - Pharmacogenomic Information: Indications and Usage. 2010, FDA.
5. Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 2009, 33(6):861-864. 10.1016/j.leukres.2008.09.026, 18986702.
6. Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 2009, 43(12):967-968. 10.1038/bmt.2008.415, 19104491.
7. Bergeron A, Rea D, Levy V, Picard C, Meignin V, Tamburini J, Bruzzoni-Giovanelli H, Calvo F, Tazi A, Rousselot P. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 2007, 176(8):814-818. 10.1164/rccm.200705-715CR, 17600277.
8. Quintás-Cardama A, Kantarjian H, O'brien S, Borthakur G, Bruzzi J, Munden R, Cortes J. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007, 25(25):3908-3914. 10.1200/JCO.2007.12.0329, 17761974.
9. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009, 34(6):1219-1263.
10. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009, 54(1 Suppl):S43-54.
11. Guilpain P, Montani D, Damaj G, Achouh L, Lefrère F, Le Pavec J, Marfaing-Koka A, Dartevelle P, Simonneau G, Humbert M, et al. Pulmonary hypertension associated with myeloproliferative disorders: a retrospective study of ten cases. Respiration 2008, 76(3):295-302. 10.1159/000112822, 18160817.
12. Harch S, Whitford H, McLean C. Failure of medical therapy in pulmonary arterial hypertension. Is there an alternative diagnosis?. Chest 2009, 135(6):1462-1469. 10.1378/chest.08-2006, 19188548.
13. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005, 115(10):2811-2821. 10.1172/JCI24838, 1236676, 16200212.
14. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005, 353(13):1412-1413. 10.1056/NEJMc051946, 16192491.
15. Patterson KC, Weissmann A, Ahmadi T, Farber HW. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 2006, 145(2):152-153.
16. Souza R, Sitbon O, Parent F, Simonneau G, Humbert M. Long term imatinib treatment in pulmonary arterial hypertension. Thorax 2006, 61(8):736. 2104679, 16877696.
17. Grinnan DC, Fairman P, Pinson J. Recurrence of severe pulmonary hypertension following the removal of a lung allograft. Chest 2007, 132(6):2057-2058. author reply 2058, 10.1378/chest.07-1724, 18079249.
18. Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, Shapiro S, Golpon H, Toshner M, Grimminger F, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010, 182(9):1171-1177. 10.1164/rccm.201001-0123OC, 3001259, 20581169.
19. Rix U, Hantschel O, Dürnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P, Colinge J, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007, 110(12):4055-4063. 10.1182/blood-2007-07-102061, 17720881.